Narrative review / 2019
Resveratrol shows therapeutic potential across various diseases in over 244 clinical trials and is reported safe at doses up to 5 g/day.
This review evaluates clinical evidence on the polyphenolic nutraceutical resveratrol, whose efficacy, safety, and pharmacokinetics have been documented in over 244 clinical trials with 27 ongoing. Resveratrol is reported to potentially improve therapeutic outcomes in conditions such as diabetes mellitus, obesity, cancers, metabolic syndrome, hypertension, Alzheimer's disease, cardiovascular diseases, and kidney diseases. It is reported to be safe at doses up to 5 g/day alone or in combination therapy. However, its therapeutic use is limited by rapid metabolism and poor bioavailability, though a micronized formulation (SRT501) shows promise.
- Study type
- Narrative review of clinical trials
- Who was studied
- Human subjects across over 244 clinical trials (with 27 ongoing)
- What was measured
- Efficacy, safety, and pharmacokinetics across various chronic diseases
THE PAPER
Health benefits of resveratrol: Evidence from clinical studies.
Singh AP, Singh R, Verma SS, Rai V, Kaschula CH, Maiti P, Gupta SC. Med Res Rev, 2019.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.